clinical trial · NCT06858735
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center·phase2·recruiting·n = 60
Advanced Intrahepatic CholangiocarcinomaDurvalumabGemcitabineCisplatin
brief summary
This study will compare outcomes for M1 iCCA patients treated with and without L-RT by reviewing iCCA patients found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT.
started
Jun 10, 2025
primary completion
Nov 19, 2028
completion
Nov 19, 2030
last updated
Mar 11, 2026
detailed description
Primary Objective:
To assess the overall survival of patients treated with standard of care systemic therapy with or without liver-directed hypofractionated adaptive RT.
Secondary Objectives:
* Patient-reported quality of life as per the FACT-Hep inventory * Progression-free survival * Cause of death
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol